Toronto, Ontario--(Newsfile Corp. - December 17, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports that the Director General of Mines under the Federal Ministry of Economy has lifted the temporary suspension notice and allowed for all activities within the Morelos Complex to resume.Jody Kuzenko, President & CEO of Torex, stated:"Following notification that the temporary suspension has been lifted by the Director General of Mines, all production and development activities at th ...

Group 1 - Torex Gold Resources Inc. reported a tragic incident at the El Limón Guajes underground mine, resulting in the deaths of two employees and one contractor due to carbon monoxide exposure [1][2] - A fourth contract employee is hospitalized but is expected to recover; the company is prioritizing support for the affected families and employees [2] - An investigation into the cause of the accident will be initiated, and all activities at the ELG Underground have been suspended [2] Group 2 - Torex Gold is an intermediate gold producer based in Canada, focusing on the exploration, development, and operation of its 100% owned Morelos Property, which spans 29,000 hectares in the Guerrero Gold Belt [3] - The Morelos Complex, the company's principal asset, includes the ELG Mine Complex and the Media Luna Project, with commercial production starting on April 1, 2016 [3] - Key strategic objectives for Torex include optimizing the Morelos Property, achieving full production at Media Luna, growing reserves, disciplined capital allocation, and enhancing ESG excellence [3]

Torex Gold Reports Compelling New Results from the 2024 ELG Underground Drilling ProgramResults continue to indicate impressive grades and ongoing potential to expand resources and replace mined reservesDecember 02, 2024 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - December 2, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces further assay results from the Compan ...

Torex Gold Reports Results From The Ongoing 2024 EPO Exploration ProgramResults indicate strong potential to upgrade Inferred Resources to Indicated Resources and expand resources to the north of the depositNovember 13, 2024 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - November 13, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) announces assay results from the Company's ...

Torex Gold Reports Q3 2024 ResultsSolid financial performance and robust cash generation driven by an all-in sustaining costs margin of 52%November 06, 2024 6:00 PM EST | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - November 6, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) reports the Company's financial and operational results for the three and nine months ended September 30, 2024. ...

10x Genomics, Inc. TXG reported a loss for the third quarter on Tuesday. The company posted a quarterly loss of 30 cents per share, compared to market expectations for a loss of 34 cents per share. The company reported quarterly sales of $151.654 million which missed the analyst consensus estimate of $158.632 million. "Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending. As ...

Financial Data and Key Metrics - Revenue for Q3 2024 declined 1% YoY to $151.7 million, driven by weaker instrument sales, particularly Xenium instruments, offset by stronger consumables revenue [5][31] - Full-year revenue guidance revised to $595 million to $605 million, representing a 3% decline from 2023 at the midpoint [5][39] - Gross margin increased to 70% from 62% YoY, driven by a shift in product mix with fewer Xenium instruments sold [35] - Operating loss for Q3 was $41.5 million, compared to a loss of $94.8 million in Q3 2023, which included $41.4 million in R&D expenses [38] - Cash and cash equivalents at the end of Q3 stood at $398.2 million [38] Business Line Performance - Chromium consumables revenue declined 4% YoY to $96.5 million, driven by lower average prices offset by higher volumes [32] - Spatial consumables revenue grew 111% YoY to $29.7 million, driven by demand for Visium HD and Xenium 5K [32] - Chromium instrument revenue declined 38% YoY to $7.6 million, while spatial instrument revenue fell 50% YoY to $11.4 million [33] - Services revenue increased 48% YoY to $6.4 million [33] Geographic Performance - Americas revenue declined 11% YoY to $87.8 million, impacted by the commercial restructuring [34] - EMEA revenue grew 18% YoY to $37.9 million, while APAC revenue increased 15% YoY to $26 million [34] Company Strategy and Industry Competition - The company is focusing on democratizing single-cell and spatial technologies by lowering price points, enhancing ease of use, and advancing product capabilities [7][8] - New product launches, such as GEM-X Flex and Chromium Xo, aim to reduce cost per cell and sample, making single-cell analysis more accessible [14][15] - The company is restructuring its commercial organization to better serve diverse customer segments, including academic and biopharma markets [10][11] - Despite challenges, the company believes it is well-positioned to lead in single-cell and spatial biology, with significant opportunities in translational research and drug development [27][28] Management Commentary on Operating Environment and Future Outlook - Management acknowledged a challenging macro environment, with cautious customer spending impacting capital purchases and larger consumables projects [5][40] - The company expects ongoing headwinds from the commercial restructuring and does not anticipate typical Q4 seasonality [40] - Management remains confident in the long-term potential of single-cell and spatial biology, with a focus on disciplined investment and cash management [9][41] Other Important Information - The company launched GEM-X Flex, reducing the cost per cell to less than $0.01, a five-fold reduction compared to previous products [14] - Chromium Xo, priced at $25,000, is the company's most affordable single-cell instrument, aimed at expanding market access [15] - The company introduced new software capabilities, such as automated cell annotation, to enhance data analysis and ease of use [19] Q&A Session Summary Question: Impact of Commercial Restructuring and Gross Margin Dynamics [45] - The company attributed half of the Q4 guidance revision to the macro environment and half to the commercial restructuring [46] - New products like GEM-X Flex and Universal Multiplex have comparable gross margins to existing consumables, supporting the company's strategy to democratize single-cell analysis [48] Question: Instrument Sales and Pricing Strategy [49] - Xenium instruments were particularly affected by the macro environment, with cautious customer spending impacting sales [50] - The company is confident in the elasticity of demand for its products, with evidence of volume growth following price reductions [52][53] Question: Progress and Metrics for Improvement [55] - Management acknowledged the challenges of 2024 but expressed confidence in the commercial restructuring, with improvements expected by mid-2025 [56][58] Question: Commercial Fixes and Timeline [60] - Filling open sales roles and implementing new processes are key priorities, with full benefits expected by mid-2025 [61][62] Question: Pricing in Single-Cell Market [64] - The company has reduced price per cell and sample through new product launches, aiming to drive market expansion [66][67] - Competition remains intense, but the company believes its product quality and pricing strategy will sustain growth [68][69] Question: Chromium Product Transition and Revenue Impact [71] - The company expects a three to four-quarter lag before volume growth offsets price reductions, with potential headwinds in the near term [72] Question: Sales Force and Xenium Installations [74] - The company is working to fill open sales roles, with normalization expected in six to nine months [74] - Xenium installations were impacted by the macro environment and commercial restructuring, but underlying demand remains strong [75][76] Question: Spatial Consumables Growth [78] - Spatial consumables revenue grew sequentially, with strong utilization trends for Xenium and Visium HD [79][91] Question: Commercial Restructuring Timeline and Macro Impact [81] - The company expects the commercial restructuring to yield benefits by mid-2025, with macro conditions assumed to remain challenging [82] Question: Expense Management and Competitive Landscape [84] - The company is balancing hiring with disciplined spending, aiming for a more efficient commercial structure [85] - Competition in single-cell remains aggressive, but the company believes its product leadership will sustain growth [86] Question: Spatial Consumables Trends [88] - Spatial consumables growth was impacted by product launches and commercial restructuring, but underlying demand remains robust [90][91] Question: Single-Cell Volume Growth [98] - Single-cell volume growth has been positive, with new products enabling higher throughput and robust cell analysis growth [100] Question: Sales Force Morale and Productivity [102] - The company is confident in its sales team's ability to adapt to the new structure, with full productivity expected by mid-2025 [103][104]

10x Genomics (TXG) reported $151.65 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 1.3%. EPS of -$0.30 for the same period compares to -$0.51 a year ago. The reported revenue represents a surprise of +0.02% over the Zacks Consensus Estimate of $151.62 million. With the consensus EPS estimate being -$0.34, the EPS surprise was +11.76%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

10x Genomics (TXG) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 11.76%. A quarter ago, it was expected that this life science technology company would post a loss of $0.47 per share when it actually produced a loss of $0.32, delivering a surprise of 31.91%. Over the last four quarters, th ...

Financial Performance - Total revenue for the three months ended September 30, 2024, was $151.654 million, compared to $153.644 million for the same period in 2023, reflecting a slight decrease[18]. - Gross profit for the nine months ended September 30, 2024, was $303.527 million, up from $293.531 million in the same period of 2023, indicating a year-over-year increase of approximately 3.4%[18]. - The net loss for the three months ended September 30, 2024, was $35.753 million, compared to a net loss of $92.986 million for the same period in 2023, representing a reduction in losses of approximately 61%[18]. - Total revenue decreased by $2.0 million, or 1%, to $151.7 million for the three months ended September 30, 2024, compared to the same period in 2023[103]. - The company incurred net losses of $35.8 million for the three months ended September 30, 2024, compared to $93.0 million for the same period in 2023[101]. Cash and Liquidity - Cash and cash equivalents increased to $398.159 million as of September 30, 2024, from $359.284 million as of December 31, 2023, showing a growth of about 10.8%[15]. - As of September 30, 2024, the company had $398.2 million in cash and cash equivalents, with an accumulated deficit of $1.4 billion since inception[115]. - The net cash provided by operating activities was $13.4 million for the nine months ended September 30, 2024, compared to a net cash used of $41.0 million for the same period in 2023[123][124]. - The company expects to continue incurring operating losses for the foreseeable future but believes existing cash and cash equivalents will meet anticipated cash needs for at least the next 12 months[119]. Expenses and Liabilities - Total current liabilities decreased to $121.235 million as of September 30, 2024, from $127.162 million as of December 31, 2023, indicating a reduction of approximately 4.7%[15]. - The company reported total operating expenses of $147.878 million for the three months ended September 30, 2024, compared to $190.324 million for the same period in 2023, reflecting a decrease of approximately 22.3%[18]. - Research and development expenses for the three months ended September 30, 2024, were $66.174 million, slightly down from $66.507 million in the same period of 2023[18]. - Selling, general and administrative expenses decreased by $0.7 million, or 1%, to $81.7 million for the three months ended September 30, 2024[109]. Assets and Equity - Total assets decreased to $937.794 million as of September 30, 2024, from $965.143 million as of December 31, 2023, representing a decline of approximately 2.8%[15]. - The company’s accumulated deficit increased to $(1,418.019) million as of September 30, 2024, from $(1,284.420) million as of December 31, 2023, indicating a rise in the deficit of approximately 10.4%[15]. - As of September 30, 2023, the total stockholders' equity was $745,216,000, with a net loss of $92,986,000 for the quarter[25]. Revenue Breakdown - Total instruments revenue for the nine months ended September 30, 2024, was $68.4 million, down 19.7% from $85.1 million in the same period of 2023[53]. - Total consumables revenue increased to $359.9 million for the nine months ended September 30, 2024, up 6.1% from $339.2 million in the same period of 2023[53]. - Instruments revenue decreased by $15.9 million, or 45%, to $19.1 million for the three months ended September 30, 2024, primarily due to lower sales of Chromium and Spatial instruments[103]. - Consumables revenue increased by $11.8 million, or 10%, to $126.2 million for the three months ended September 30, 2024, driven by higher Spatial consumables sales[103]. Legal Matters - The Company was awarded over $31 million in damages from NanoString, including approximately $25 million in lost profits and $6 million in royalties[60]. - The jury found that NanoString willfully infringed the asserted patents, and the Company is seeking a permanent injunction and ongoing royalties[60]. - The Company filed a second suit against NanoString alleging infringement of U.S. Patent Nos. 10,227,639 and 11,021,737, with discovery currently in progress[61]. - The Company is involved in multiple legal actions against NanoString, including a counterclaim regarding the Company's Visium products[65]. Stock and Compensation - The weighted-average shares of common stock used in computing net loss per share, basic and diluted, were 120,733,030 for the three months ended September 30, 2024, compared to 117,728,293 for the same period in 2023[18]. - The Company reported stock-based compensation expense of $33.91 million for the three months ended September 30, 2024, compared to $40.24 million for the same period in 2023, reflecting a decrease of approximately 16.5%[86]. - The total number of shares of Class A common stock issued and outstanding as of September 30, 2024, was 106,983,035, with 14,056,833 shares of Class B common stock also outstanding[84]. Future Outlook - The company anticipates capital expenditures of approximately $15 million to $20 million over the next 12 months, focusing on manufacturing and R&D[116]. - The company regularly reviews acquisition and investment opportunities to support long-term growth objectives, which may significantly increase capital needs[118].